Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. Yam C, et al. Among authors: symmans wf. Invest New Drugs. 2021 Apr;39(2):509-515. doi: 10.1007/s10637-020-00995-2. Epub 2020 Sep 28. Invest New Drugs. 2021. PMID: 32984932 Clinical Trial.
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.
Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Symmans WF, et al. Cancer. 2003 Jun 15;97(12):2960-71. doi: 10.1002/cncr.11435. Cancer. 2003. PMID: 12784330 Free article.
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Pusztai L, et al. Among authors: symmans wf. Clin Cancer Res. 2003 Jul;9(7):2406-15. Clin Cancer Res. 2003. PMID: 12855612
Breast cancer biomarkers and molecular medicine.
Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Ross JS, et al. Among authors: symmans wf. Expert Rev Mol Diagn. 2003 Sep;3(5):573-85. doi: 10.1586/14737159.3.5.573. Expert Rev Mol Diagn. 2003. PMID: 14510178 Review.
Targeted therapy in breast cancer: the HER-2/neu gene and protein.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Ross JS, et al. Among authors: symmans wf. Mol Cell Proteomics. 2004 Apr;3(4):379-98. doi: 10.1074/mcp.R400001-MCP200. Epub 2004 Feb 3. Mol Cell Proteomics. 2004. PMID: 14762215 Free article. Review.
Breast cancer biomarkers and molecular medicine: part II.
Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Ross JS, et al. Among authors: symmans wf. Expert Rev Mol Diagn. 2004 Mar;4(2):169-88. doi: 10.1586/14737159.4.2.169. Expert Rev Mol Diagn. 2004. PMID: 14995904 Review.
297 results